AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis

Aug 16 2021

• By Sue Sutter

AVEO's Fotivda made it to the US market only after the FDA resolved lingering concerns about the drug's impact on overall survival.

More from Drug Review Profiles

More from Product Reviews